SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.

Vir Biotechnology, a US-based immunology drug developer backed by telecommunications group SoftBank, will float today in a $143m initial public offering on the Nasdaq Global Select Market.

The company priced approximately 7.14 million shares on the low end of the IPO’s $20 to $22 range, valuing it at about $2.19bn.

Joint book-running managers Goldman Sachs, JP Morgan Securities, Cowen and Company and Barclays Capital have 30 days to buy up to 1.07 million more shares to lift the size…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn